Gilteritinib after stem cell transplant for leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies the immune system's response when a drug called gilteritinib is given after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how gilteritinib affects your immune system and if it helps prevent the leukemia from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have received a stem cell transplant from a matched relative, matched unrelated donor, mismatched unrelated donor, or half-matched (haploidentical) donor for acute myeloid leukemia.
- Your doctor plans to give you gilteritinib as maintenance therapy after your transplant.
- You are not pregnant.
- You have not been treated for a solid tumor in the last 2 years.
- You do not have active hepatitis B or C, HIV, or a known allergy to gilteritinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
This trial tests a new combination of chemotherapy (FLAI) and a targeted drug (Gilteritinib) for adults with acute myeloid leukemia (AML) that has a specific genetic change called FLT3. It aims to see if the combo works better than standard treatment.
This trial tests an oral drug called gilteritinib for people with advanced ALK-positive non-small cell lung cancer that has progressed after prior ALK inhibitor treatment. It aims to see if gilteritinib can help when other treatments have stopped working.
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
This Phase 1 study tests how well gilteritinib works when combined with either ivosidenib or enasidenib in adults with relapsed or refractory acute myeloid leukemia (AML). It targets specific genetic changes in the leukemia and may help shrink or control the cancer when standard options haven’t worked.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.